Immune response markers in sentinel nodes may predict melanoma progression.

Oncoimmunology 2014 15;3:e28498. Epub 2014 Apr 15.

Unit of Immunotherapy; Fondazione IRCCS Istituto Nazionale Tumori; Milan, Italy.

We recently reported that variable expression of immune-response genes distinguishes tumor positive sentinel nodes in melanoma patients with malignant progression from those with non-progressing disease. Our results depict sentinel nodes as sites in which immune functions are associated with metastatic disease and identify CD30 as a host immune-related cancer prognostic marker and potential therapeutic target.

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.28498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063153PMC
April 2014
12 Reads

Publication Analysis

Top Keywords

sentinel nodes
12
disease depict
4
non-progressing disease
4
depict sentinel
4
nodes sites
4
immune functions
4
sites immune
4
progression non-progressing
4
positive sentinel
4
tumor positive
4
nodes melanoma
4
melanoma patients
4
patients malignant
4
functions associated
4
associated metastatic
4
prognostic marker
4
cancer prognostic
4
marker potential
4
potential therapeutic
4
therapeutic target
4

Similar Publications